ZEISS Launches Dedicated Cataract Surgery System at ESCRS

Event summary

ZEISS debuts the DORC EVA NEXUS ophthalmic surgical system in a dedicated cataract configuration at the ESCRS congress in London.
The system features a cataract grade selection with up to four programmable pre-sets for optimized phaco, aspiration, and irrigation settings.
The solution will be available first in select European countries beginning in September 2026, with global availability pending regulatory approvals.
The system integrates advanced technologies like VacuFlow VTi pump, SMART IOP™, and EVA EQUIPHACO™ for enhanced performance, stability, and control.

The big picture

ZEISS's launch of the DORC EVA NEXUS cataract configuration underscores the company's strategic focus on specialized surgical solutions. The move aligns with broader industry trends towards precision medicine and advanced surgical technologies, positioning ZEISS to capture a larger share of the growing cataract surgery market. With over 5,700 employees and €2.228 billion in revenue for fiscal year 2024/25, ZEISS is well-positioned to leverage its technological advancements to maintain its leadership in the ophthalmic surgical systems sector.

What we're watching

Regulatory Approvals: The pace at which ZEISS secures regulatory approvals for global availability of the DORC EVA NEXUS cataract configuration.
Market Adoption: How the tailored approach and advanced features of the DORC EVA NEXUS will influence surgeon preference and market share in cataract surgery systems.
Technological Integration: Whether the integration with the ZEISS Cataract Workflow will enhance procedural efficiency and surgical outcomes, driving further adoption.